REDWOOD CITY, California, April 30, 2026
Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2 DAZALS clinical trial evaluating dazucorilant, a selective cortisol modulator, in patients with amyotrophic lateral sclerosis (ALS). The study demonstrated an 87% reduction in risk of death (hazard ratio: 0.13, p<0.0001) among patients treated with the 300 mg dose, marking one of the most striking survival benefits reported in ALS clinical research. These findings position dazucorilant as a potentially disease-modifying therapy in a condition where treatment options remain extremely limited and prognosis is poor.
Strong Survival Benefit Despite Primary Endpoint Miss
The DAZALS study was a randomized, double-blind, placebo-controlled Phase 2 trial involving 249 ALS patients, assessing two dose levels of dazucorilant (150 mg and 300 mg) versus placebo over a 24-week treatment period, followed by a long-term extension phase. While the trial did not meet its primary endpoint related to functional improvement measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), the secondary endpoint of overall survival showed highly significant benefit.
Patients receiving 300 mg dazucorilant daily exhibited consistent survival advantages at both one-year (84% risk reduction) and two-year (87% risk reduction) milestones. Importantly, patients who continued on the higher dose beyond 24 weeks maintained a 61% reduction in mortality risk at two years, reinforcing the durability of the treatment effect. This disconnect between functional outcomes and survival raises critical questions but also highlights the potential of survival as a more meaningful endpoint in ALS trials.
Novel Cortisol Modulation Approach Targets Disease Biology
Advertisement
Dazucorilant represents a first-in-class selective cortisol modulator that targets the glucocorticoid receptor, addressing a growing body of evidence linking abnormal cortisol signaling to ALS progression. Unlike traditional therapies that primarily manage symptoms, this approach aims to modify underlying disease mechanisms, potentially slowing neurodegeneration.
Elevated cortisol levels have been associated with accelerated disease progression and reduced survival in ALS patients, making this pathway an attractive therapeutic target. By selectively modulating cortisol activity without broadly suppressing other hormone systems, dazucorilant offers a more precise and potentially safer strategy. The drug has already received Fast Track Designation and Orphan Drug status from the U.S. Food and Drug Administration, reflecting both its innovation and the urgent unmet need in ALS treatment.
Safety Profile and Next Development Steps
Dazucorilant demonstrated an acceptable safety profile, with the most common adverse event being mild-to-moderate, transient abdominal pain, which appeared dose-related. To further optimize tolerability, Corcept is currently conducting a dose titration study aimed at minimizing gastrointestinal side effects while preserving efficacy. Based on the strong survival data, the company plans to initiate a pivotal Phase 3 trial later in 2026, in close collaboration with regulatory authorities.
However, there is a clear challenge: regulators will likely demand robust confirmation of both survival and functional benefit, especially given the primary endpoint miss in Phase 2. If Phase 3 can replicate the survival advantage while demonstrating at least modest functional improvement, dazucorilant could become a transformational therapy in ALS care.
Implications for ALS Treatment Landscape
ALS, also known as Lou Gehrig’s disease, is a rapidly progressive neurodegenerative disorder with a typical life expectancy of two to five years after diagnosis. Current therapies offer only limited survival extension, making the magnitude of benefit observed with dazucorilant particularly noteworthy.
If validated in larger trials, this therapy could shift the treatment paradigm from symptomatic management to true disease modification, offering patients extended survival and improved quality of life during the early stages of the disease. At the same time, the results highlight a broader issue in neurodegenerative drug development—the need to rethink clinical endpoints and prioritize outcomes that matter most to patients, such as survival.
Corcept’s findings represent a high-risk, high-reward scenario. The survival signal is unusually strong, but the lack of primary endpoint success introduces uncertainty. The next phase of development will be critical in determining whether dazucorilant can transition from promising experimental therapy to a new standard of care in ALS.
Source: Corcept Therapeutics press release
